Bordetella Pertussis Toxoid Vaccine, Inactivated
The Bordetella Pertussis Toxoid Vaccine, Inactivated is a vaccine designed to provide active immunization against pertussis (whooping cough), a highly contagious respiratory infection caused by Bordetella pertussis bacteria. This inactivated toxoid vaccine stimulates the immune system to produce protective antibodies without causing the disease. It is typically administered as part of routine childhood immunization schedules or in outbreak situations.
An inactivated vaccine that protects against pertussis (whooping cough) by stimulating the immune system to produce protective antibodies against Bordetella pertussis.
Key facts at a glance
- RxNorm
- 1300186
- Generic
- Bordetella Pertussis Toxoid Vaccine, Inactivated
- Class
- pin-variant
- Brands
- Quadracel, Vaxelis, Infanrix, Daptacel, Boostrix, Adacel
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 0.5 mL
- Maximum
- consult physician
- Frequency
- primary series at 2, 4, 6, and 15-18 months with booster at 4-6 years
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.5 mL
- Maximum
- consult physician
- Frequency
- single dose as Tdap, then Td booster every 10 years
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.5 mL
- Maximum
- consult physician
- Frequency
- single dose of Tdap if not previously received, then Td booster every 10 years
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
7 groupspregnancy
second third trimesterstandard_dose
ACIP recommends Tdap vaccine during every pregnancy, preferably between 27-36 weeks gestation to maximize passive antibody transfer to the fetus
standard prenatal care
pregnancy
first trimesterstandard_dose
vaccination may be administered if needed, but preferred timing is second/third trimester; defer if possible until recommended gestational window
standard prenatal care
Use with caution and monitor for adverse effects.
lactation
breastfeeding mothersstandard_dose
Tdap vaccination is recommended for breastfeeding mothers who have not previously received Tdap during current pregnancy; safe to administer while breastfeeding
none required beyond standard
pediatric_age
infants 2 months to 7 yearsstandard_dose
DTaP vaccine recommended for primary series at 2, 4, 6, and 15-18 months with booster at 4-6 years; acellular pertussis component is well-tolerated
standard pediatric immunization monitoring
geriatric
65 years and olderstandard_dose
CDC recommends one dose of Tdap if not previously received, followed by Td or Tdap booster every 10 years; particularly important for grandparents and caregivers of infants
standard post-vaccination observation
renal_impairment
all stagesstandard_dose
vaccine may be administered at standard dosing; no dosage adjustment necessary for any stage of renal impairment including dialysis patients
standard vaccination monitoring
hepatic_impairment
all stagesstandard_dose
vaccine may be administered at standard dosing; no dosage adjustment necessary for any stage of hepatic impairment including cirrhosis
standard vaccination monitoring
Statistics and clinical data
Commonly prescribed since
First acellular pertussis vaccine approval in the United States
Drug class
Vaccine classification for pertussis prevention
Common uses
Primary indication for pertussis-containing vaccines
Target population
Recommended age groups for vaccination
Prevention of pertussis (whooping cough) caused by Bordetella pertussis infection. Used in routine childhood immunization and for post-exposure prophylaxis in outbreak situations.
Contains inactivated pertussis toxoid that stimulates the immune system to produce neutralizing antibodies against the pertussis toxin, providing active immunity without causing disease.
Administered via intramuscular injection. Common side effects include injection site reactions, mild fever, and fussiness. Contraindicated in individuals with severe allergic reactions to previous doses. Not a substitute for treatment of active infection.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy